TAMPA, Fla. — Neutra Corp. (OTCQB:NTRR) joint venture partner Oceanview Health Services Ltd. is making the necessary preparations to debut a new brand of cannabis-infused topical products, BeKind Topicals, in markets where cannabis is legal and regulated.
NTRR formed its joint venture with the Vancouver-based Oceanview last month. Oceanview is working on new formulas for cutting-edge topical creams, oils, salves, lotions and more that have been infused with medicinal cannabis. Major revenues could potentially be derived from licensing the brand and its recipes to top distributors in territories with regulated medical cannabis marketplaces.
The joint venture was formed to capitalize on cannabis topicals’ booming popularity among cannabis patients. BeKind Topicals products could soon prove useful in treating a wide variety of health issues, such as arthritis, muscle soreness, nerve pain and more.
“Topicals are undoubtedly one of the fastest-growing segments in the North American cannabis industry,” said NTRR CEO Chris Brown. “Our partnership with Oceanview has our company well-positioned to succeed in the rapidly emerging marketplace. Demand for these products appears to be growing by the day wherever cannabis is legal.”
In 2016, NTRR plans to deliver many new offerings for cannabis producers and consumers alike as the regulated cannabis industry continues to swell in the United States, Canada and beyond.
About Neutra Corp.
As the global cannabis market grows exponentially, it is constantly in need of better technologies and products to be more efficient in how they grow, what they grow, and how they consume cannabis and its related products. From lighting to dosage devices, from pesticide replacements to plant enhancers, NTRR is constantly combing the industry for the latest and greatest to test, prove and bring to market.
By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (NASDAQ: GWPH), Cara Therapeutics Inc. (NASDAQ: CARA) and 22nd Century Group, Inc. (NASDAQ: XXII). For investing information and performance data, please visit www.neutracorp.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Chris Brown, 813-367-2041
President and CEO